vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $30.3M, roughly 1.1× SYPRIS SOLUTIONS INC). SYPRIS SOLUTIONS INC runs the higher net margin — -12.9% vs -299.9%, a 287.0% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -9.5%). Over the past eight quarters, Karyopharm Therapeutics Inc.'s revenue compounded faster (1.4% CAGR vs -7.7%).
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
KPTI vs SYPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $30.3M |
| Net Profit | $-102.2M | $-3.9M |
| Gross Margin | — | 4.6% |
| Operating Margin | -52.4% | -10.9% |
| Net Margin | -299.9% | -12.9% |
| Revenue YoY | 11.6% | -9.5% |
| Net Profit YoY | -232.0% | -2992.6% |
| EPS (diluted) | $-7.02 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $30.3M | ||
| Q3 25 | $44.0M | $28.7M | ||
| Q2 25 | $37.9M | $31.4M | ||
| Q1 25 | $30.0M | $29.5M | ||
| Q4 24 | $30.5M | $33.4M | ||
| Q3 24 | $38.8M | $35.7M | ||
| Q2 24 | $42.8M | $35.5M | ||
| Q1 24 | $33.1M | $35.6M |
| Q4 25 | $-102.2M | $-3.9M | ||
| Q3 25 | $-33.1M | $517.0K | ||
| Q2 25 | $-37.3M | $-2.1M | ||
| Q1 25 | $-23.5M | $-899.0K | ||
| Q4 24 | $-30.8M | $135.0K | ||
| Q3 24 | $-32.1M | $390.0K | ||
| Q2 24 | $23.8M | $16.0K | ||
| Q1 24 | $-37.4M | $-2.2M |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | 8.1% |
| Q4 25 | -52.4% | -10.9% | ||
| Q3 25 | -34.6% | -6.1% | ||
| Q2 25 | -64.3% | -4.6% | ||
| Q1 25 | -110.8% | -0.4% | ||
| Q4 24 | -102.4% | 3.9% | ||
| Q3 24 | -67.8% | 4.8% | ||
| Q2 24 | -65.7% | 3.6% | ||
| Q1 24 | -101.9% | -3.9% |
| Q4 25 | -299.9% | -12.9% | ||
| Q3 25 | -75.2% | 1.8% | ||
| Q2 25 | -98.2% | -6.5% | ||
| Q1 25 | -78.2% | -3.0% | ||
| Q4 24 | -100.8% | 0.4% | ||
| Q3 24 | -82.7% | 1.1% | ||
| Q2 24 | 55.6% | 0.0% | ||
| Q1 24 | -112.8% | -6.2% |
| Q4 25 | $-7.02 | $-0.17 | ||
| Q3 25 | $-3.82 | $0.02 | ||
| Q2 25 | $-4.32 | $-0.09 | ||
| Q1 25 | $-2.77 | $-0.04 | ||
| Q4 24 | $-2.33 | $0.00 | ||
| Q3 24 | $-3.85 | $0.02 | ||
| Q2 24 | $-2.97 | $0.00 | ||
| Q1 24 | $-4.85 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $17.8M |
| Total Assets | $108.4M | $107.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | — | ||
| Q3 25 | $37.7M | — | ||
| Q2 25 | $38.7M | — | ||
| Q1 25 | $38.8M | — | ||
| Q4 24 | $62.5M | — | ||
| Q3 24 | $72.8M | — | ||
| Q2 24 | $84.8M | — | ||
| Q1 24 | $30.6M | — |
| Q4 25 | $-292.9M | $17.8M | ||
| Q3 25 | $-269.3M | $20.0M | ||
| Q2 25 | $-238.9M | $18.7M | ||
| Q1 25 | $-205.9M | $19.0M | ||
| Q4 24 | $-186.0M | $19.6M | ||
| Q3 24 | $-159.6M | $18.2M | ||
| Q2 24 | $-132.1M | $19.0M | ||
| Q1 24 | $-169.0M | $20.8M |
| Q4 25 | $108.4M | $107.8M | ||
| Q3 25 | $96.2M | $112.5M | ||
| Q2 25 | $104.9M | $105.8M | ||
| Q1 25 | $127.7M | $110.2M | ||
| Q4 24 | $164.4M | $119.4M | ||
| Q3 24 | $189.5M | $121.6M | ||
| Q2 24 | $214.0M | $124.2M | ||
| Q1 24 | $204.5M | $129.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $-1.1M |
| Free Cash FlowOCF − Capex | — | $-1.5M |
| FCF MarginFCF / Revenue | — | -5.0% |
| Capex IntensityCapex / Revenue | 0.0% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $-1.1M | ||
| Q3 25 | $-5.9M | $-178.0K | ||
| Q2 25 | $-18.7M | $1.1M | ||
| Q1 25 | $-39.0M | $-5.5M | ||
| Q4 24 | $-25.8M | $2.3M | ||
| Q3 24 | $-19.5M | $-4.8M | ||
| Q2 24 | $-38.5M | $6.2M | ||
| Q1 24 | $-43.7M | $-1.7M |
| Q4 25 | — | $-1.5M | ||
| Q3 25 | — | $-390.0K | ||
| Q2 25 | — | $941.0K | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | $-25.9M | $1.9M | ||
| Q3 24 | — | $-4.9M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | $-43.9M | $-2.0M |
| Q4 25 | — | -5.0% | ||
| Q3 25 | — | -1.4% | ||
| Q2 25 | — | 3.0% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | -84.7% | 5.7% | ||
| Q3 24 | — | -13.8% | ||
| Q2 24 | — | 16.8% | ||
| Q1 24 | -132.6% | -5.7% |
| Q4 25 | 0.0% | 1.3% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.2% | 1.2% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.6% | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | -1.62× | 385.25× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
